English | 简体中文 | 繁體中文 | 한국어 | 日本語
Friday, 28 January 2022, 18:08 HKT/SGT
Share:
IgY antibody technology against SARS-CoV-2 unveiled

HONG KONG, Jan 28, 2022 - (ACN Newswire) - An IgY neutralizing antibody, which is claimed to inhibit the activity of SARS-CoV-2, the novel coronavirus that causes COVID-19, by over 99 percent, was launched in Shenzhen on Monday, according to Shenzhen Special Zone Daily.

The IgY antibody technology, with an invention patent issued by China National Intellectual Property Association, was jointly unveiled by Sino-Swed Tongkang Biotech Ltd. (Shenzhen) and a local precision medicine research institute.

After the COVID-19 outbreak in 2020, the two developers leveraged their strength in antibody engineering technology and began to develop antibodies that can specifically inhibit SARS-CoV-2 under the guidance of Swedish scientist Sven Skog, according to the Daily report.

The IgY antibody that shows inhibitory activity against SARS-CoV-2 was extracted and obtained from the yolks of eggs delivered by immunized hens.

The results from the Shenzhen Center for Disease Control and Prevention's BSL-3 laboratory in October 2020 showed that the inhibitory effect of the disinfectant containing the antibody on a wild-type novel coronavirus reached 99.85 percent.

The experimental results from the State Key Laboratory of Virology in December 2021 showed that spray prepared by the antibody has an inhibitory effect of 99.94 percent on the Delta variant.

It is reported that the IgY antibody would not cause irritation or toxic side effects to the human body and can work on the body's mucosal surfaces or on objects' surfaces.

It has an inhibitory effect on the novel coronavirus for up to three hours per single use.

http://www.szlhq.gov.cn/english/news/content/post_9528020.html

Source: Shenzhen Daily


Topic: Press release summary Sectors: BioTech, Healthcare & Pharm
https://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2022 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.

 

Latest Press Releases
B20 ESC Task Force to link performance, SDG targets with policies  
May 27, 2022 23:00 HKT/SGT
CNERGENZ Berhad Posts RM36.9 Million in Revenue for 1Q FY2022  
May 27, 2022 21:00 HKT/SGT
New WARC Awards for Effectiveness, North America Edition, in association with LIONS, are launched  
May 27, 2022 19:00 HKT/SGT
IBI Announces Acquisition of Strategic Property Investment in Europe  
May 27, 2022 17:48 HKT/SGT
Toyota Announces Adjustments to Domestic Production in June  
Friday, May 27, 2022 4:54:00 PM
TOYOTA GAZOO Racing Targets Gravel Double in Sardinia  
Friday, May 27, 2022 4:27:00 PM
GPDRR: Indonesia offers sustainable resilience to tackle disaster risk  
May 27, 2022 13:00 HKT/SGT
Eisai Contributes to the Science of Cancer Medicine at ASCO 2022  
Friday, May 27, 2022 11:49:00 AM
Eisai: MHLW Grants Orphan Drug Designation in Japan to Mecobalamin Ultrahigh-Dose Formulation with Prospective Indication for Delaying the Progression of Disease and Functional Impairment of ALS  
Friday, May 27, 2022 11:24:00 AM
Hong Kong 'ideal listing destination' for ASEAN companies  
May 27, 2022 11:00 HKT/SGT
More Press release >>
 Events:
More events >>
Copyright © 2022 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Cookies Policy | Privacy Policy | Disclaimer | Terms of Use | RSS
US: +1 214 890 4418 | Beijing: +86 400 879 3881 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575